Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 182

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

Targeting the renin–angiotensin system as novel therapeutic strategy for pulmonary diseases

Tan, Wan Shun Daniel, Liao, Wupeng, Zhou, Shuo, Mei, Dan, Wong, Wai-Shiu Fred · 2018 · Current Opinion in Pharmacology

Abstract

HighlightsRenin angiotensin system (RAS) is believed to play a major role in regulating electrolyte balance and blood pressure.Recent studies have implicated RAS contributing to inflammatory pulmonary diseases.Inhibition of the angiotensin I (Ang I)/Ang II/angiotensin type 1 receptor (AT1R) pathway alleviates inflammatory lung diseases.Stimulation of the angiotensin‐converting enzyme 2 (ACE2)/Ang (1–7)/Mas receptor pathway is a novel drug development strategy for the treatment of pulmonary diseases.Genetic screening and combination therapy may optimize personalized therapies for inflammatory lung diseases. &NA; The renin–angiotensin system (RAS) plays a major role in regulating electrolyte balance and blood pressure. RAS has also been implicated in the regulation of inflammation, proliferation and fibrosis in pulmonary diseases such as asthma, acute lung injury (ALI), chronic obstructive pulmonary disease (COPD), idiopathic pulmonary fibrosis (IPF) and pulmonary arterial hypertension (PAH). Current therapeutics suffer from some drawbacks like steroid resistance, limited efficacies and side effects. Novel intervention is definitely needed to offer optimal therapeutic strategy and clinical outcome. This review compiles and analyses recent investigations targeting RAS for the treatment of inflammatory lung diseases. Inhibition of the upstream angiotensin (Ang) I/Ang II/angiotensin receptor type 1 (AT1R) pathway and activation of the downstream angiotensin‐converting enzyme 2 (ACE2)/Ang (1–7)/Mas receptor pathway are two feasible strategies demonstrating efficacies in various pulmonary disease models. More recent studies favor the development of targeting the downstream ACE2/Ang (1–7)/Mas receptor pathway, in which diminazene aceturate, an ACE2 activator, GSK2586881, a recombinant ACE2, and AV0991, a Mas receptor agonist, showed much potential for further development. As the pathogenesis of pulmonary diseases is so complex that RAS modulation may be used alone or in combination with existing drugs like corticosteroids, pirfenidone/nintedanib or endothelin receptor antagonists for different pulmonary diseases. Personalized medicine through genetic screening and phenotyping for angiotensinogen or ACE would aid treatment especially for non‐responsive patients. This review serves to provide an update on the latest development in the field of RAS targeting for pulmonary diseases, and offer some insights into future direction.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.coph.2017.12.002

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 2 references

Cited by

See all 182

Metadata

Authors
Tan, W. S. D., Liao, W., Zhou, S., Mei, D., & Wong, W.-S. F.
Venue
Current Opinion in Pharmacology
Publisher
Elsevier BV
Published
2018-06
Volume
40
Pages
9-17
ISSN
1471-4892 (ISSN-L)
OpenAlex
W2778600864
Cited by
182
References
2
FWCI
4.71
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Targeting the renin–angiotensin system as novel therapeutic strategy for pulmonary diseases. https://app.cochat.ai/papers/10.1016/j.coph.2017.12.002
The paper
Tan, W. S. D., Liao, W., Zhou, S., Mei, D., & Wong, W.-S. F. (2018). Targeting the renin–angiotensin system as novel therapeutic strategy for pulmonary diseases. Current Opinion in Pharmacology. https://doi.org/10.1016/j.coph.2017.12.002

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.